News

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) (the “Company” or “Acadia”) announced today that it has launched a private offering (the “Offering”) of $500 million in aggregate principal amount of

ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink

Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in a fireside chat at the Leerink

Novocure (NASDAQ: NVCR) announced today that management will participate in the Leerink Global Healthcare Conference on Tuesday, March 11, 2025. Christoph Brackmann, Chief Financial Officer, will

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will attend the

Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 35th Annual Healthcare Conference on Monday, March 17, 2025, at approximately 9:20 a.m

Personalis, Inc. (Nasdaq: PSNL), in collaboration with Professor Nick Turner, Dr. Isaac Garcia-Murillas and their colleagues at The Institute of Cancer Research, London and The Royal Marsden NHS

Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the fourth quarter and year ended December 31, 2024.

“We are pleased with the progress that we have made against the strategy

ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA PME), a next generation biopharma company dedicated to the development of innovative biomedicines based on a recombinant apolipoprotein

Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference at

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons

Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the fourth quarter and year ended December 31, 2024.

Fourth Quarter 2024

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46^th Annual Raymond James Institutional Investors Conference on Tuesday, March 4^th.

The

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results

Novocure (NASDAQ: NVCR) today reported financial results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working to extend survival in some of the most

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve months ended December 31, 2024 and provided an update on recent corporate progress.

Fourth